Biologics Market Size to Boost USD 719.14 Billion By 2030 | CAGR 7.8% - Published by Emergen Research

The global biologics market is projected to reach USD 719.14 Billion in 2030 at a steady revenue CAGR of 7.8% over the forecast period, according to latest analysis by Emergen Research. Some key factors attributed to steady market revenue growth include rising demand for monoclonal antibodies, recombinant hormones/proteins, gene-based & cellular-based biologics, vaccines, and molecular therapy, etc. in the treatment of diseases including cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others. Also, rising use of biologics for the treatment of autoimmune diseases, comprising various arthritis types, including ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis, is playing a crucial role in driving revenue growth of the global biologics market. Biologics function by creating an inflammation disruption, thereby resulting in a reduction in joint pain.

Surging demand and higher adoption of novel biologics drugs and therapies across the globe for the treatment of disease conditions is a significant factor causative of steady market revenue growth. One such novel drug is Antibody-Drug Conjugate (ADC), which is a highly effective drug used in disease treatment. In cancer treatment, ADC delivers drugs to the disease/target cells with a very high specificity, thereby maximizing efficacy and lessening systemic exposure, as well as associated side effect risks. Based on payload attached to the antibody, ADC can be deployed to influence several biological functions.

The report is attuned with the latest market changes and economic landscape with regard to the currently unfolding COVID-19 pandemic. The crisis has affected the demand and supply pattern, as well as the trends of the industry. It has also brought an economic slowdown that has affected the business of the key manufacturers of the industry. The report estimates the impact of this crisis on the current scenario and future prospects and provides a post-COVID market scenario.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/61

Drivers of Biologics Market Growth :

Several factors are propelling the growth of the biologics market. Firstly, the rising incidence of chronic diseases such as cancer, autoimmune disorders, and metabolic diseases has created a significant unmet medical need, driving the demand for innovative biologic therapies. Additionally, technological advancements in bioprocessing, such as recombinant DNA technology and protein engineering, have enabled the development of novel biologics with improved efficacy and safety profiles. Moreover, favorable regulatory policies and expedited approval pathways for biologics have accelerated market entry and commercialization, fostering competition and innovation in the industry.

Restraints Challenging Biologics Market :

Despite its promising growth prospects, the biologics market faces several challenges. One of the primary obstacles is the high cost of biologic therapies, which can limit patient access and affordability, particularly in developing countries and underinsured populations. Additionally, the complexity of manufacturing biologics, including stringent quality control requirements and the need for specialized facilities, contributes to high production costs and supply chain challenges. Furthermore, intellectual property issues, such as patent expirations and biosimilar competition, pose threats to market exclusivity and revenue streams for biologic manufacturers.

The report also discusses the key players involved in the market such as:

Novo Nordisk A/S, Pfizer Inc., Amgen, Sanofi, Samsung BioLogics, Merck & Co. Inc., Celltrion, AbbVie Inc., Johnson & Johnson Services Inc., Eli Lilly & Company, F Hoffman La Roche, Addgene, Novartis AG, and GlaxoSmithKline.

The report provides a thorough estimation of the overall impact of the pandemic on the Biologics Market and its vital segments. The report also discusses the impact of the pandemic across different regions of the market. It also offers a current and future assessment of the impact of the pandemic on the Biologics Market

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/61

Biologics Latest Industry News :

On 21 December 2021, Sanofi announced the acquisition of Amunix Pharmaceuticals, Inc., an immuno-oncology company that uses its proprietary, clinically validated XTEN as well as innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-Cell Engagers (TCE) and cytokine therapies for cancer patients. According to the terms of the settlement, Sanofi will pay an upfront payment of roughly USD 1 billion and up to USD 225 million if certain future development milestones are met. With around 20 compounds under development, the purchase complements Sanofi's ambitions to expedite and broaden its contributions to novel treatments for cancer patients.

On 10 March 2020, GT Biopharma, Inc., a business that concentrates on creating innovative treatments based on its proprietary NK cell engager (TriKE) platform, announced a collaboration agreement with Cytovance Biologics, Contract Development and Manufacturing Organization (CDMO) based in the United States and a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a publicly traded company with a market capitalization of USD 4.39 billion, to provide development services.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @  https://www.emergenresearch.com/select-license/61

 Biologics Market Segment Analysis :

For the purpose of this report, Emergen Research has segmented the biologics market on the basis of source, product type, application, and region:

Source Outlook (Revenue, USD Million; 2019-2030)
Microbial
Mammalian
Others
Product Type Outlook (Revenue, USD Million; 2019-2030)
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-Based Biologics
Gene-Based Biologics
Others
Application Outlook (Revenue, USD Million; 2019-2030)
Cancer
Infectious Diseases
Immunological Diseases
Cardiovascular Disorders
Hematological Disorders
Others
Regional Outlook (Revenue, USD Million, 2019-2030)
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
BENELUX
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
Israel
Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/biologics-market

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.